A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
Abroad (travel likely)RecruitingPHASE2
Conditions
Idiopathic Pulmonary Fibrosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
PHI University Clinic of Pulmonology and Allergology, Skopje, North Macedonia
Contact: Principal Investigator (Dejan V Dokic)
Study leads
Vincent COTTIN
Principal Investigator
Louis Pradel Hospital - Lyon, FRANCE